To address this and allow more robust assessments of the role of BAF genomic lesions as predictors of therapeutic outcomes in NSCLC, several key factors will need to be considered, including the type of mutation (type 1 vs. type 2, homozygous vs. heterozygous), its functional consequences (complete, partial, or no protein expression), and the presence of comutations such as STK11 and KEAP1 both within and outside (e.g., other oncogenes or tumor suppressors) the BAF complex. This evidence concerns the gene BANF1 and non-small cell lung carcinoma.